NYSE:CCChemours Stock Price, Forecast & News

$15.75

+0.95 (+6.42 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$14.56

Now: $15.75▼

$15.76

50-Day Range

$9.31

MA: $11.88▼

$14.80

52-Week Range

$7.02

Now: $15.75▼

$25.35

Volume2.55 million shs

Average Volume1.95 million shs

Market Capitalization$2.59 billion

P/E RatioN/A

Dividend Yield6.76%

Beta2.42

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging. The Fluoroproducts segment provides fluoroproducts, including refrigerants, and industrial fluoropolymer resins and derivatives under the Teflon, Viton, Krytox, and Nafion brand names. The Chemical Solutions segment offers industrial and specialty chemicals for gold production, oil and gas, water treatment, electronics, and automotive industries. It also provides sodium cyanide through its mining solutions business; and performance chemicals and intermediates, such as methylamines, glycolic acid, and Vazo free radical initiators. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.

Beat the Market (BTM) Rank^™

2.1 Analyst's Opinion

Consensus Rating
Chemours has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.30, Chemours has a potential downside of 2.9% from its current price of $15.75.
Amount of Analyst Coverage
Chemours has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.3 Community Rank

Outperform Votes
Chemours has received 588 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Chemours has received 665 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Chemours has received 53.07% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Chemours and other stocks. Vote “Outperform” if you believe CC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CC will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Chemours is a leading dividend payer. It pays a dividend yield of 6.76%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Chemours has only been increasing its dividend for 2 years.
Dividend Coverage
The dividend payout ratio of Chemours is 39.84 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Chemours will have a dividend payout ratio of 48.78 % next year. This indicates that Chemours will be able to sustain or increase its dividend.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chemours insiders have bought more of their company's stock than they have sold. Specifically, they have bought $140,700.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.72% of the stock of Chemours is held by insiders.
Percentage Held by Institutions
80.10% of the stock of Chemours is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Chemours are expected to grow by 38.51% in the coming year, from $1.48 to $2.05 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chemours is -52.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chemours is -52.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chemours has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Chemicals & allied products

Sub-IndustryN/A

SectorBasic Materials

Current SymbolNYSE:CC

Previous Symbol

CUSIPN/A

CIK1627223

Webwww.chemours.com

Phone302-773-1000

Debt

Debt-to-Equity Ratio6.42

Current Ratio1.93

Quick Ratio1.10

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio10.64

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.53 billion

Price / Sales0.47

Cash Flow$4.82 per share

Price / Cash Flow3.27

Book Value$4.25 per share

Price / Book3.71

Profitability

EPS (Most Recent Fiscal Year)$2.51

Net Income$-52,000,000.00

Net Margins-0.82%

Return on Equity56.54%

Return on Assets5.88%

Miscellaneous

Employees7,000

Outstanding Shares164,220,000

Market Cap$2.59 billion

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive CC News and Ratings via Email

Sign-up to receive the latest news and ratings for CC and its competitors with MarketBeat's FREE daily newsletter.

Chemours (NYSE:CC) Frequently Asked Questions

How has Chemours' stock been impacted by COVID-19 (Coronavirus)?

Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CC stock has increased by 47.7% and is now trading at $15.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chemours?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Chemours.

When is Chemours' next earnings date?

Chemours is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Chemours.

How were Chemours' earnings last quarter?

Chemours Co (NYSE:CC) posted its quarterly earnings data on Tuesday, May, 5th. The specialty chemicals company reported $0.71 EPS for the quarter, beating the Zacks' consensus estimate of $0.46 by $0.25. The specialty chemicals company earned $1.31 billion during the quarter, compared to the consensus estimate of $1.33 billion. Chemours had a positive return on equity of 56.54% and a negative net margin of 0.82%. The business's quarterly revenue was down 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. View Chemours' earnings history.

How often does Chemours pay dividends? What is the dividend yield for Chemours?

Chemours declared a quarterly dividend on Tuesday, April 28th. Stockholders of record on Friday, May 15th will be given a dividend of $0.25 per share on Monday, June 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 6.35%. The ex-dividend date is Thursday, May 14th. View Chemours' dividend history.

What price target have analysts set for CC?

11 brokers have issued 12 month price targets for Chemours' shares. Their forecasts range from $8.00 to $30.00. On average, they expect Chemours' share price to reach $15.30 in the next twelve months. This suggests that the stock has a possible downside of 2.9%. View analysts' price targets for Chemours.

Has Chemours been receiving favorable news coverage?

News articles about CC stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chemours earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned media coverage about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutChemours.

Are investors shorting Chemours?

Chemours saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 15,120,000 shares, a decline of 5.2% from the April 30th total of 15,950,000 shares. Based on an average trading volume of 3,730,000 shares, the days-to-cover ratio is presently 4.1 days. Approximately 9.3% of the company's shares are short sold. View Chemours' Current Options Chain.

Who are some of Chemours' key competitors?

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), W. R. Grace & Co (GRA), SHOWA DENKO KK/ADR (SHWDY), Balchem (BCPC), Univar (UNVR), Ingevity (NGVT), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Hawkins (HWKN). View all competitors.

What other stocks do shareholders of Chemours own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA) and Energy Transfer LP Unit (ET).

Who are Chemours' key executives?

Chemours' management team includes the following people:

Mr. Mark P. Vergnano, Pres, CEO & Director (Age 61)
Mr. Mark E. Newman, Sr. VP & CFO (Age 56)
Mr. David C. Shelton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
Mr. E. Bryan Snell, Pres of Titanium Technologies (Age 62)
Mr. Paul Kirsch, Pres of Fluoroproducts Bus. (Age 55)

What is Chemours' stock symbol?

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Who are Chemours' major shareholders?

Chemours' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.61%), State Street Corp (2.45%), Bank of New York Mellon Corp (1.85%), Invesco Ltd. (1.55%), Luminus Management LLC (1.48%) and Geode Capital Management LLC (1.14%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View institutional ownership trends for Chemours.

Which institutional investors are selling Chemours stock?

CC stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Deutsche Bank AG, Invesco Ltd., Parametric Portfolio Associates LLC, Principal Financial Group Inc., and Retirement Systems of Alabama. View insider buying and selling activity for Chemours.

Which institutional investors are buying Chemours stock?

CC stock was acquired by a variety of institutional investors in the last quarter, including Luminus Management LLC, Two Sigma Advisers LP, DC Investments Management LLC, DNB Asset Management AS, Thrivent Financial for Lutherans, JPMorgan Chase & Co., Advisors Asset Management Inc., and Voloridge Investment Management LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher. View insider buying and selling activity for Chemours.

How do I buy shares of Chemours?

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chemours' stock price today?

One share of CC stock can currently be purchased for approximately $15.75.

How big of a company is Chemours?

Chemours has a market capitalization of $2.59 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

What is Chemours' official website?

The official website for Chemours is www.chemours.com.

How can I contact Chemours?

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff